The DOI matches its Crossref record; 105 of the 105 references it cites were found in a registry or an index.
Overcoming cellular barriers for RNA therapeutics
Abstract
RNA-based therapeutics, such as small-interfering (siRNAs), microRNAs (miRNAs), antisense oligonucleotides (ASOs), aptamers, synthetic mRNAs and CRISPR-Cas9, have great potential to target a large part of the currently undruggable genes and gene products and to generate entirely new therapeutic paradigms in disease, ranging from cancer to pandemic influenza to Alzheimer's disease. However, for these RNA modalities to reach their full potential, they first need to overcome a billion years of evolutionary defenses that have kept RNAs on the outside of cells from invading the inside of cells. Overcoming the lipid bilayer to deliver RNA into cells has remained the major problem to solve for widespread development of RNA therapeutics, but recent chemistry advances have begun to penetrate this evolutionary armor.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As an emerging programmable gene interference technique, siRNA offers high specificity and flexibility in targeting the diseased human genome [236].”
From Emerging role of exosomes in cancer therapy: progress and challenges (2025) · cites this paper as [236]
In the citing paper
“Many obstacles still exist despite the rise in studies on delivery platforms, including toxicity and the precise distribution of mRNA to extrahepatic organs [13, 14].”
From Exosome for mRNA delivery: Strategies and therapeutic applications (2024) · cites this paper as [13]
In the citing paper
“Independent of the administration route, several evolutionary barriers are designed to prevent any intrusion of foreign nucleic acids and thus limit the delivery of exogenous mRNA [74].”
From Three decades of messenger RNA vaccine development (2019) · cites this paper as [74]
In the citing paper
“For instance, RNA interference (RNAi) technology enables the downregulation of disease related genes and protein expression; mRNA mediates the expression and supplementation of therapeutic proteins; the CRISPR gene editing system facilitates gene engineering in vivo or through cell engineering ex vivo.[6, 9, 11, 17–20]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [19]
In the citing paper
“For instance, RNA interference (RNAi) technology enables the downregulation of disease related genes and protein expression; mRNA mediates the expression and supplementation of therapeutic proteins; the CRISPR gene editing system facilitates gene engineering in vivo or through cell engineering ex vivo.[6, 9, 11, 17–20]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [19]
In the citing paper
“For instance, RNA interference (RNAi) technology enables the downregulation of disease related genes and protein expression; mRNA mediates the expression and supplementation of therapeutic proteins; the CRISPR gene editing system facilitates gene engineering in vivo or through cell engineering ex vivo.[6, 9, 11, 17–20]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [19]
In the citing paper
“With the development of chemical modifications on RNA molecules, modified siRNA are reported to remain intact for long durations under circulation, which provides the possibility of delivering siRNA without the shielding of nanoparticles.[19, 75, 76]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [19]
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans
Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., & Mello, C. C. (1998) · Nature · doi:10.1038/35888 · Cited by 15,429
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., & Tuschl, T. (2001) · Nature · doi:10.1038/35078107 · Cited by 9,456
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Direct Gene Transfer into Mouse Muscle in Vivo
Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., & Felgner, P. L. (1990) · Science · doi:10.1126/science.1690918 · Cited by 4,173
Doherty, G. J., & McMahon, H. T. (2009) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.78.081307.110540 · Cited by 3,075
In vivo genome editing using Staphylococcus aureus Cas9
Ran, F. A., Cong, L., Yan, W. X., Scott, D. A., Gootenberg, J. S., Kriz, A. J., Zetsche, B., Shalem, O., Wu, X., Makarova, K. S., et al. (2015) · Nature · doi:10.1038/nature14299 · Cited by 2,687
Research works printed but not linked: 2
- Rich, A. in Horizons In Biochemistry (eds. Kasha, M. & Pullman, B.) 103–126 (Academic Press, New York, 1962).
- Cummings, R. & McEver, R. in Essentials of Glycobiology. 2nd edn. (eds. Varki, A. et al.) Chapter 31 (Cold Spring Harbor (NY); Cold Spring Harbor Laboratory Press, 2009).
Cited by
Sorted by citations
Items 701–800 of 1,000
Gustafsson, O., Krishna, S., Borate, S., Ghaeidamini, M., Liang, X., Saher, O., Cuellar, R., Birdsong, B. K., Roudi, S., Estupiñan, H. Y., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114038 · Cited by 11
Design of Cyclic Peptide-Based Nanospheres and the Delivery of siRNA
Ke, J., Zhang, J., Li, J., Liu, J., & Guan, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012071 · Cited by 10
Emerging therapies in hereditary ataxias
Eisel, M. L. S., Burns, M., Ashizawa, T., Byrne, B. J., Corti, M., & Subramony, S. H. (2024) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2024.07.008 · Cited by 10
Wang, J., Dai, J., Yang, X., Yu, X., Emory, S. R., Yong, X., Jin-hua, X., Mei, L., Xie, J., Han, N., et al. (2018) · Nanoscale · doi:10.1039/c8nr06191b · Cited by 10
Potent and Selective Knockdown of Tyrosine Kinase 2 by Antisense Oligonucleotides
van Tran, N., Nguyen, L. T. A., Lim, K. W., & Phan, A. T. (2021) · ImmunoHorizons · doi:10.4049/immunohorizons.2000108 · Cited by 12
Wei, R., Hu, Q. Z., Lu, Y., & Wang, X. (2022) · Current Alzheimer Research · doi:10.2174/1567205019666220613142303 · Cited by 10
Targeting Liver Xor by GalNAc-siRNA Is an Effective Strategy for Hyperuricemia Therapy
Sun, H., Wang, X., Li, Y., Shen, Y., Zhang, L., Xu, Y., Liu, J., & Fan, X. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16070938 · Cited by 9
Wu, Q., Zhou, Y., Yan, J., Li, X. J., Meng, F., Wang, B., & Yin, L. (2024) · Nano Today · doi:10.1016/j.nantod.2024.102444 · Cited by 9
Rodent models in sensorineural hearing loss research: A comprehensive review
Li, W., Xu, B., Huang, Y., Wang, X., & Yu, D. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.123156 · Cited by 10
An insight into cancer nanomedicine based on polysaccharides
Chakraborty, D. D., Chakraborty, P., & Mondal, A. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.138678 · Cited by 9
Integrating Machine Learning-Based Approaches into the Design of ASO Therapies
Leckie, J., & Yokota, T. (2025) · Genes · doi:10.3390/genes16020185 · Cited by 9
Chen, L., Bosmajian, C., & Woo, S. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102516 · Cited by 9
RNA-based therapeutic opportunities for the treatment of kidney diseases
Prins, J., Biscans, A., van Zonneveld, A. J., Frazier, K. S., & van der Veer, E. P. (2025) · Nature Reviews Nephrology · doi:10.1038/s41581-025-01011-7 · Cited by 11
Targeting the Eye: RNA-Based Therapies, Interferences, and Delivery Strategies
Abdel‐Raziq, M. S., Zhong, C., Hassan, F. E., & Li, S. K. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17101326 · Cited by 11
Galanopoulos, M., Doukatas, A., Gkeros, F., Viazis, N., & Liatsos, C. N. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i24.3568 · Cited by 9
Iqbal, S., Luo, B., Melamed, J. R., & Day, E. S. (2021) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.1c00405 · Cited by 9
Gene Regulation Using Nanodiscs Modified with HIF-1-α Antisense Oligonucleotides
Sharma, R., Dong, Y., Hu, Y., Ma, V. P.-Y., & Salaita, K. S. (2022) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.1c00505 · Cited by 9
Chen, Y., Zhao, R., Li, L., & Zhao, Y. (2022) · Angewandte Chemie · doi:10.1002/ange.202206485 · Cited by 9
Aderinto, N., Muili, A. O., Olatunji, G. D., Edun, M. T., & Aboderin, G. (2023) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000001118 · Cited by 9
Merckx, P., Conickx, G., Blomme, E. E., Maes, T., Bracke, K. R., Brusselle, G., Smedt, S. C. D., & Raemdonck, K. (2024) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2024.114223 · Cited by 9
Wen, X., Shao, Z., Chen, X., Liu, H., Qiu, H., Ding, X., Qu, D., Wang, H., Wang, A. Z., & Zhang, L. (2024) · Radiation Oncology · doi:10.1186/s13014-024-02511-9 · Cited by 9
Lee, J. H., Park, E.-B., Min, J., Sung, S.-E., Jang, Y., Shin, J. S., Chun, D., Kim, K., Hwang, J., Lee, M., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky039 · Cited by 9
RetractedKrooss, S. A., Werwitzke, S., Kopp, J., Rovai, A., Varnholt, D., Wachs, A. S., Goyenvalle, A., Aartsma-Rus, A. M., Ott, M., Tiede, A., et al. (2020) · PLoS Genetics · doi:10.1371/journal.pgen.1008690 · Cited by 9
A Nanoplasmonic Assay of Oligonucleotide‐Cargo Delivery from Cationic Lipoplexes
Kho, K. W., Berselli, G. B., & Keyes, T. E. (2021) · Small · doi:10.1002/smll.202005815 · Cited by 10
Pal, S., Chakraborty, H., & Chattopadhyay, A. (2021) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.1c02499 · Cited by 9
Synthesis of KUE‐siRNA Conjugates for Prostate Cancer Cell‐Targeted Gene Silencing
Yang, C., Ma, D., Lu, L., Yang, X., & Xi, Z. (2021) · ChemBioChem · doi:10.1002/cbic.202100243 · Cited by 9
Fernandes, M., Marques, H., Teixeira, A. L., & Medeiros, R. (2021) · Cancers · doi:10.3390/cancers13246324 · Cited by 9
RNA Epigenetics in Chronic Lung Diseases
Wang, X., Guo, Z., & Yan, F. (2022) · Genes · doi:10.3390/genes13122381 · Cited by 9
Ding, W., Yang, X., Lin, H., Xu, Z., Wang, J., Dai, J., Xu, C., Chen, F., Wen, X., Chai, W., et al. (2023) · Nano Letters · doi:10.1021/acs.nanolett.2c04834 · Cited by 8
Zhang, J., Liu, Y., Zeng, H., Zhao, Z., Han, Y., Zhao, Y., Qu, S., Gong, Z., Wang, Z., Bai, Y., et al. (2024) · ACS Nano · doi:10.1021/acsnano.4c05475 · Cited by 9
Cao, Y., Zhao, Z., Fang, J., Lu, Y., Huang, Z., Wu, G., Gao, Q., Li, R., Xu, L., & Xu, X. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202500646 · Cited by 8
Gene expression silencing therapy in tumors, focus on gastrointestinal and genitourinary tumors
El-Ghazzi, N., Italiano, A., & Angeli, E. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1657040 · Cited by 10
mRNA-LNP vaccines: rational design, delivery optimization, and clinical translation
Jiang, S., & Lu, Z. (2025) · Journal of Materials Chemistry B · doi:10.1039/d5tb01972a · Cited by 10
Cui, S., Wu, X., Yu, X., Huang, Y., Zhang, D., Chen, H., Heng, B. C., Cai, Q., Wang, Y., Gu, Y., et al. (2025) · Advanced Materials · doi:10.1002/adma.202410507 · Cited by 10
Virus-Inspired mRNA Delivery Vehicle Enabled by a Multilayered Nucleic Acid Nanocapsule
Pal, S., Singla, D., Canete, R. C., Darkwah, J. B., Cannata, J. N., Hunte, M. L., Penales, I. B., Szczepanek, S. M., Ducongè, F., Smilowitz, H. M., et al. (2025) · ACS Nano · doi:10.1021/acsnano.5c12871 · Cited by 10
Chien, K. R., Foo, K. S., & Witman, N. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-026-01459-7 · Cited by 12
8–17 DNAzyme Silencing Gene Expression in Cells via Cleavage and Antisense
Zhou, Z., Sun, W. C., & Huang, Z. (2022) · Molecules · doi:10.3390/molecules28010286 · Cited by 8
Using RNA-based therapies to target the kidney in cardiovascular disease
Palmer, T., & Hunter, R. W. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1250073 · Cited by 8
Ge, Y., Li, W., Tian, J., Yu, H., Wang, Z., Wang, M., & Dong, Z. (2024) · Advanced Science · doi:10.1002/advs.202400678 · Cited by 8
Advances in Antisense Oligo Technology for Sustainable Crop Protection
Patil, V., Jangra, S., & Ghosh, A. (2024) · Critical Reviews in Plant Sciences · doi:10.1080/07352689.2024.2394001 · Cited by 8
Synthesis and characterization of 4′- C -guanidinomethyl-2′- O -methyl-modified RNA oligomers
Uematsu, A., Kajino, R., Maeda, Y., & Ueno, Y. (2019) · Nucleosides Nucleotides & Nucleic Acids · doi:10.1080/15257770.2019.1666277 · Cited by 8
Intracellular Delivery of Antisense DNA and siRNA with Amino Groups Masked with Disulfide Units
Shu, Z., Ota, A., Takayama, Y., Katsurada, Y., Kusamori, K., Abe, N., Nakamoto, K., Tomoike, F., Tada, S., Ito, Y., et al. (2020) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c19-00811 · Cited by 8
Ansari, A. S., Remant, K. C., Jiang, X., & Uludağ, H. (2021) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.37214 · Cited by 7
RAB18 is a key regulator of GalNAc-conjugated siRNA-induced silencing in Hep3B cells
Lu, J., Swearingen, E., Hardy, M., Collins, P. J., Wu, B., Yuan, E., Lu, D., Li, C.-M., Wang, S., & Ollmann, M. M. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.04.003 · Cited by 8
Perfluoroalkyl-containing Compounds as a Tool for Drug Delivery Systems
Aikawa, K., & Okazoe, T. (2022) · Royal Society of Chemistry eBooks · doi:10.1039/9781839167591-00477 · Cited by 9
Pulling the trigger: Noncoding RNAs in white adipose tissue browning
Liang, D., & Li, G. (2023) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-023-09866-6 · Cited by 8
Peng, Z., Wenru, Z., Dai, J., & Fang, J. (2018) · Cellular and Molecular Biology · doi:10.14715/cmb/2018.64.6.14 · Cited by 8
Role of Helicity in DNA Hairpin Folding Dynamics
Li, H., & Kabakçıoğlu, A. (2018) · Physical Review Letters · doi:10.1103/physrevlett.121.138101 · Cited by 8
Francisco, V., Rebelo, C., Rodrigues, A. F., Blersch, J., Fernandes, H., & Ferreira, L. (2020) · Methods · doi:10.1016/j.ymeth.2020.12.002 · Cited by 8
Beals, N., Farhath, M. M., Kharel, P., Croos, B., Mahendran, T., Johnson, J., & Basu, S. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.05.013 · Cited by 8
Cell Penetrating Peptide-Based Self-Assembly for PD-L1 Targeted Tumor Regression
Guo, F., Ke, J., Fu, Z., Han, W., & Wang, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413314 · Cited by 8
Drug nanorods are potential new nanocarriers for intracellular protein delivery
Gao, W., & Sun, M. (2018) · Theranostics · doi:10.7150/thno.27815 · Cited by 8
Therapeutic targeting of RNA for neurological and neuromuscular diseasePreprint
Bubenik, J. L., Scotti, M. M., & Swanson, M. S. (2024) · Genes & Development · doi:10.1101/gad.351612.124 · Cited by 8
Sioud, M. (2023) · Scandinavian Journal of Immunology · doi:10.1111/sji.13282 · Cited by 8
Fan, J., Xiao, Z., Dong, Y., Ye, F., Yan, Q., Zhang, C., Yin, X., Li, Y., & Wang, T. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202402933 · Cited by 7
Harnessing Computational Strategies to Overcome Challenges in mRNA Vaccines
Zhao, S., Chen, J., Dai, T., Li, G., Huang, L., Xin, J., Zhang, Y., Chen, Y., He, X., Huang, H., et al. (2025) · Physiology · doi:10.1152/physiol.00047.2024 · Cited by 7
Luo, Y., Wang, X., Li, Y., Duan, D., Liu, K., Lei, M., Zhang, L., & Zhu, Y. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.144962 · Cited by 7
Chemical Modifications in Nucleic Acid Therapeutics
Lennox, K. A., Young, R. C., & Behlke, M. A. (2025) · Methods in molecular biology · doi:10.1007/978-1-0716-4742-4_3 · Cited by 8
Volovăț, S. R., Augustin, I. G., Volovat, C. D., Ingrid, T. V., Ostafe, M. R., Panaite, D. I., Burlacu, A. I., & Volovăț, C. C. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18010084 · Cited by 8
Feng, M., Liu, J., Wang, L., & Swevers, L. (2026) · Frontiers in Insect Science · doi:10.3389/finsc.2025.1749008 · Cited by 7
Engineering the Future: Strategic Advances in Extracellular Vesicle-Mediated Drug Delivery Systems
Zhang, X., & Zhang, X. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s583242 · Cited by 9
Kajino, R., Sakamoto, S., & Ueno, Y. (2022) · RSC Advances · doi:10.1039/d2ra00705c · Cited by 7
Intracellular Communication between Synthetic Macromolecules
Evans, C. W., Ho, D., Marlow, J. B., King, J. J., Hee, C., Wong, L. N., Atkin, R., Smith, N. M., Warr, G. G., Nörret, M., et al. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c02793 · Cited by 7
Dong, Z., Jia, L., Han, W., Wang, Y., Sheng, M., Ren, Y., Weng, Y., Li, H., & Yu, W. (2023) · Cellular Signalling · doi:10.1016/j.cellsig.2023.110668 · Cited by 7
Overcoming delivery barriers for RNA therapeutics in the treatment of rheumatoid arthritis
Zhang, B., Li, J., Jiang, J., Lin, X., Sun, X., & Wang, Q. (2023) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2023.10.010 · Cited by 8
Advances in RNA therapeutics for modulation of ‘undruggable’ targets
Martinsen, E., Jinnurine, T., Subramani, S., & Rogne, M. (2024) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2023.12.003 · Cited by 7
InflammamiRs in focus: Delivery strategies and therapeutic approaches
Akkaya‐Ulum, Y. Z., Şen, B., Akbaba, T. H., & Balcı‐Peynircioğlu, B. (2024) · The FASEB Journal · doi:10.1096/fj.202302028r · Cited by 7
Broc, B., Varini, K., Sonnette, R., Pecqueux, B., Benoist, F., Thomas, M., Masse, M., Mechioukhi, Y., Ferracci, G., David, M., et al. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16040548 · Cited by 8
Efficient siRNA delivery to murine melanoma cells via a novel genipin-based nano-polymer
Pelle, G. D., Božič, T., Vukomanović, M., Serša, G., Markelc, B., & Kostevšek, N. (2024) · Nanoscale Advances · doi:10.1039/d4na00363b · Cited by 7
Cong, H., Hu, J., Wang, J., Chang, B., Li, R., Cui, X., Zhang, C., Ji, H., Lin, C., Tang, J., et al. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.125054 · Cited by 7
Glenister, M. A., Mistarz, U. H., Cook, K., Stephenson, J. L., & Dickman, M. J. (2025) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.10033 · Cited by 7
Stone, P. T., Kwiatkowski, A. J., Roth, E. W., Fedorova, O., Pyle, A. M., & Wilson, J. T. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c00125 · Cited by 7
Jaiprasart, P., Yeung, B. Z., Lu, Z., Wientjes, M. G., Cui, M., Hsieh, C., Woo, S., & Au, J. L. ‐. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.12.001 · Cited by 7
Effect of modular conjugation strategy forN-acetylgalactosamine-targeted antisense oligonucleotides
Yamamoto, T., Sawamura, M., Terada, C., Kashiwada, K., Wada, F., Yamayoshi, A., Obika, S., & Harada‐Shiba, M. (2019) · Nucleosides Nucleotides & Nucleic Acids · doi:10.1080/15257770.2019.1677911 · Cited by 7
Unresolved Issues in RNA Therapeutics in Vascular Diseases With a Focus on Aneurysm Disease
Schellinger, I. N., Dannert, A., Mattern, K., Raaz, U., & Tsao, P. S. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.571076 · Cited by 8
Elucidating miRNA Function in Cancer Biology via the Molecular Genetics’ Toolbox
Azlan, A., Rajasegaran, Y., Khor, K. Z., Rosli, A. A., Yik, M. Y., Yusoff, N. M., Heidenreich, O. T., & Moses, E. J. (2022) · Biomedicines · doi:10.3390/biomedicines10040915 · Cited by 8
Wang, H., Su, Y., Chen, D., Li, Q., Shi, S., Huang, X., Fang, M., & Yang, M. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1119431 · Cited by 7
mRNA as a medicine in nephrology: the future is now
Granata, S., Stallone, G., & Zaza, G. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad196 · Cited by 7
Non-Coding RNAs in Kidney Stones
Wang, G., Mi, J., Bai, J., He, Q., Li, X., & Wang, Z. (2024) · Biomolecules · doi:10.3390/biom14020213 · Cited by 7
Liang, W., Xi, H., Yuhua, L., Lili, W., Wang, Z., Ziwei, Z., Wang, C., Aizhen, C., Wu, X., Wei, B., et al. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.04.067 · Cited by 7
Kajino, R., & Ueno, Y. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115925 · Cited by 7
The OP Protein Cage: A Versatile Molecular Delivery Platform
Edwardson, T. G. W., Levasseur, M. D., & Hilvert, D. (2021) · CHIMIA International Journal for Chemistry · doi:10.2533/chimia.2021.323 · Cited by 7
Mammalian oocytes receive maternal-effect RNAs from granulosa cellsPreprint
Doherty, C. A., Tijjani, A., Munger, S. C., & Laird, D. J. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.10.637575 · Cited by 7
Delivery Strategies of siRNA Therapeutics for Hair Loss Therapy
Jin, S., & Sung, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147612 · Cited by 9
High-resolution visualisation of antisense oligonucleotide release from polymers in cells
King, J. J., Chen, K., Evans, C. W., Nörret, M., Almasri, R., Pavlos, N. J., Hui, H. Y. L., Lin, Q., Bhatt, U., Young, S. G., et al. (2024) · Chemical Science · doi:10.1039/d3sc06773d · Cited by 6
Amphiphilic Oligonucleotide Derivatives—Promising Tools for Therapeutics
Bauer, I., & Dmitrienko, E. V. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16111447 · Cited by 6
Bai, J., Zhao, B., Ma, Y., Li, W., Feng, P., & Hua, Y. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.02.032 · Cited by 6
Liu, Y., Quan, Y., Mao, Q., Xu, R., & Tai, W. (2025) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5c00212 · Cited by 6
RNA‐Based Therapeutics: Cutting‐Edge Advances in Clinical Research
Ferreira, D., & Rodrigues, L. R. (2025) · Advanced Therapeutics · doi:10.1002/adtp.202500082 · Cited by 7
Bird, S. M., Smith, C., Habibi, N., Rivera, S., Mortezazadeh, S., Martin, R., Geilich, B., Besin, G., & Demeler, B. (2025) · Advanced Functional Materials · doi:10.1002/adfm.202523042 · Cited by 6
Leckie, J., Wu, S. Z., Standell, T., & Yokota, T. (2025) · Genes · doi:10.3390/genes16121468 · Cited by 7
Harnessing RNA molecules for therapy: advances in design, delivery, and clinical development
Zou, J., He, X., Li, Z., Song, B., Xing, X., Yu, J., & He, W. (2025) · Targetome · doi:10.48130/targetome-0025-0003 · Cited by 7
Nanomaterial-enabled RNA therapeutics: bridging delivery barriers to clinical translation
Pandey, K., Jha, S., Chaliha, L. B., Gosai, H. B., & Patel, R. (2026) · Frontiers in Nanotechnology · doi:10.3389/fnano.2026.1860221 · Cited by 7
Optical Penetration of Shape-Controlled Metallic Nanosensors across Membrane Barriers
Da, A., Chu, Y., Krach, J., Liu, Y., Park, Y., & Lee, S. E. (2023) · Sensors · doi:10.3390/s23052824 · Cited by 6
Engineering Nanomedicine for Non-Viral RNA-Based Gene Therapy of Glioblastoma
He, W., Wang, N., Wang, Y.-P., Liu, M., Qing, Q., Su, Q., Zou, Y., & Liu, Y. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16040482 · Cited by 6
Pawar, S., Pingale, P., Garkal, A., Osmani, R. A. M., Gajbhiye, K. R., Kulkarni, M., Pardeshi, K., Mehta, T. A., & Rajput, A. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.131139 · Cited by 6
Zhu, M., Chen, X., Zhang, Y., Yang, C., Wu, J., & Duan, X. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124689 · Cited by 6
Roldán, E. L., Stelinski, L. L., & Pelz‐Stelinski, K. S. (2024) · Pest Management Science · doi:10.1002/ps.8552 · Cited by 6
Singh, S., Khan, S., Khan, S., Ansari, O., Malhotra, N., Shukla, S. K., & Narang, J. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00664 · Cited by 7
Recent strategies for enhanced delivery of mRNA to the lungs
Heiser, B. J., Veyssi, A., & Ghosh, D. (2025) · Nanomedicine · doi:10.1080/17435889.2025.2485669 · Cited by 7
Metadata
- Authors
- Dowdy, S. F.
- Affiliations
- University of California San Diego (US)
- Corresponding author
- Dowdy, Steven F
- ORCID
- Dowdy, Steven F
- Venue
- Nature Biotechnology
- Published
- 2017-02-27
- Volume
- 35
- Issue
- 3
- Pages
- 222-229
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W2594133976
- Cited by
- 1,139
- References
- 105
- Citations by year
- 2026: 103 · 2025: 130 · 2024: 147 · 2023: 133 · 2022: 130 · 2021: 141 · 2020: 104 · 2019: 88 · 2018: 120 · 2017: 41
- FWCI
- 9.04
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Nature Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
- Keywords
- RNA therapeutics, RNA delivery, lipid bilayers, siRNA, microRNA, antisense oligonucleotides, aptamers, synthetic mRNA, CRISPR/Cas9
- MeSH terms
- RNAi Therapeutics, Animals, Cell Membrane, Humans, RNA, RNA Interference, Nanocapsules, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
